CSF and Plasma Amyloid-β Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury

Scientific Reports

Volumn 3, Issue , 2014, Pages

  Mondello, Stefania ^a   Buki, Andras ^b   Barzo, Pal ^c   Randall, Jeff ^d   Provuncher, Gail ^d   Hanlon, David ^d   Wilson, David ^d   Kobeissy, Firas ^e   Jeromin, Andreas ^d  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d QUANTERIX CORPORATION   (United States)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; BLOOD; BRAIN; BRAIN INJURY; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLASGOW COMA SCALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AMYLOID BETA-PEPTIDES; BRAIN; BRAIN INJURIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLASGOW COMA SCALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 84938678331     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06446     Document Type: Article

References (30)

1. Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-9 (1985).
2. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-44 (2010).
3. Shively, S., Scher, A. I., Perl, D. P. & Diaz-Arrastia, R. Dementia resulting from traumatic brain injury: what is the pathology? Arch Neurol 69, 1245-51 (2012).
4. McKee, A. C. et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43-64 (2013).
5. Stern, R. A. et al. Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM R 3, S460-7 (2011).
6. Brody, D. L. et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321, 1221-4 (2008).
7. Magnoni, S. & Brody, D. L. New perspectives on amyloid-beta dynamics after acute brain injury: moving between experimental approaches and studies in the human brain. Arch Neurol 67, 1068-73 (2010).
8. Marklund, N. et al. Monitoring of beta-Amyloid Dynamics after Human Traumatic Brain Injury. J Neurotrauma (2013).
9. Jack, C. R., Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-28 (2010).
10. Roberts, G. W., Gentleman, S. M., Lynch, A. & Graham, D. I. beta A4 amyloid protein deposition in brain after head trauma. Lancet 338, 1422-3 (1991).
11. Strozyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF Abeta 42 levels correlate with amyloid-neuropathologyinapopulation-based autopsy study. Neurology 60, 652-6 (2003).
12. Shlosberg, D., Benifla, M., Kaufer, D. & Friedman, A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 6, 393-403 (2010).
13. Tsitsopoulos, P. P. & Marklund, N. Amyloid-beta Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies. Front Neurol 4, 79 (2013).
14. Franz, G. et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60, 1457-61 (2003).
15. Kay, A. D. et al. Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury. J Neurotrauma 20, 943-952 (2003).
16. Olsson, A. et al. Marked increase of beta-amyloid((1-42)) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 251, 870-876 (2004).
17. Marklund, N. et al. Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg 110, 1227-37 (2009).
18. Marshall, L. F. et al. A new classification of head injury based on computerized tomography. J Neurosurg 75 (SUPPL.), S14-S20 (1991).
19. Skandsen, T. et al. Prevalence and impact of diffuse axonal injury in patients with moderate and severe head injury: a cohort study of early magnetic resonance imaging findings and 1-year outcome. J Neurosurg 113, 556-63 (2010).
20. Mehta, P. D., Pirttila, T., Patrick, B. A., Barshatzky, M. & Mehta, S. P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304, 102-6 (2001).
21. Hansson, O. et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-67 (2010).
22. Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4, 147ra111 (2012).
23. Vanderstichele, H. et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-58 (2000).
24. Marti-Fabregas, J. et al. Prognostic value of plasma beta-amyloid levels in patients with acute intracerebral hemorrhage. Stroke 45, 413-7 (2014).
25. Hernandez-Guillamon, M. et al. Plasma beta-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis 10, 320-3 (2012).
26. Mondello, S., Buki, A., Italiano, D. & Jeromin, A. alpha-Synuclein in CSF of patients with severe traumatic brain injury. Neurology (2013).
27. Mondello, S. et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15, R156 (2011).
28. Raabe, A. et al. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir 140, 787-792 (1998).
29. Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28, 595-9 (2010).
30. Zetterberg, H. et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One 6, e28263 (2011).